Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients

Transplant Proc. 2000 Feb;32(1A Suppl):6S-8S. doi: 10.1016/s0041-1345(00)00808-3.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arteriosclerosis / prevention & control
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use
  • Female
  • Graft Rejection / epidemiology
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Kidney Transplantation / immunology
  • Kidney Transplantation / physiology*
  • Male
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Pilot Projects
  • Safety

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Mycophenolic Acid